Dynavax Technologies Corporation (DVAX) to Release Earnings on Monday
Dynavax Technologies Corporation (NASDAQ:DVAX) will be releasing its earnings data before the market opens on Monday, November 6th. Analysts expect Dynavax Technologies Corporation to post earnings of ($0.53) per share for the quarter.
Dynavax Technologies Corporation (NASDAQ:DVAX) last posted its quarterly earnings data on Wednesday, August 2nd. The biopharmaceutical company reported ($0.41) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.50) by $0.09. Dynavax Technologies Corporation had a negative return on equity of 92.09% and a negative net margin of 1,323.99%. The firm had revenue of $0.11 million for the quarter, compared to analyst estimates of $0.15 million. During the same quarter last year, the company earned ($0.75) EPS. On average, analysts expect Dynavax Technologies Corporation to post $-1.74 EPS for the current fiscal year and $-1.27 EPS for the next fiscal year.
Dynavax Technologies Corporation (DVAX) opened at 21.70 on Monday. Dynavax Technologies Corporation has a 1-year low of $3.20 and a 1-year high of $24.45. The firm’s 50-day moving average price is $21.42 and its 200-day moving average price is $12.90. The company’s market cap is $1.19 billion.
DVAX has been the topic of a number of analyst reports. Zacks Investment Research raised shares of Dynavax Technologies Corporation from a “hold” rating to a “buy” rating and set a $11.00 target price on the stock in a report on Monday, July 10th. Royal Bank Of Canada set a $7.00 target price on shares of Dynavax Technologies Corporation and gave the company a “hold” rating in a report on Wednesday, July 26th. William Blair reissued an “outperform” rating on shares of Dynavax Technologies Corporation in a report on Thursday, July 27th. Cowen and Company reissued an “outperform” rating and set a $45.00 target price on shares of Dynavax Technologies Corporation in a report on Thursday, July 27th. Finally, J P Morgan Chase & Co raised shares of Dynavax Technologies Corporation from a “neutral” rating to an “overweight” rating and boosted their target price for the company from $6.00 to $27.00 in a report on Monday, July 31st. Three research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $25.00.
Dynavax Technologies Corporation Company Profile
Dynavax Technologies Corporation is a clinical-stage immunotherapy company. The Company is focused on leveraging the body’s innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma.
Receive News & Ratings for Dynavax Technologies Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies Corporation and related companies with MarketBeat.com's FREE daily email newsletter.